                               SEQUENCE LISTING

<110> BAYLOR COLLEGE OF MEDICINE
 
<120> CD1D-RESTRICTED NKT CELLS AS A PLATFORM FOR OFF-THE-SHELF CANCER
      IMMUNOTHERAPY

<130> BAYM.P0236WO

<140>
<141>

<150> EP 17185992.9
<151> 2017-08-11

<160> 13    

<170> PatentIn version 3.5

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 1
ggccacggag cgagacatct                                                   20


<210> 2
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 2
gtaccggagg tttgaagatg ccgcatttct cgagaaatgc ggcatcttca aacctttttt       60

tg                                                                      62


<210> 3
<211> 58
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 3
ccggctggtc tttctatctc ttgtactcga gtacaagaga tagaaagacc agtttttg         58


<210> 4
<211> 58
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 4
ccggcagcag agaatggaaa gtcaactcga gttgactttc cattctctgc tgtttttg         58


<210> 5
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 5
cggtccgaca ttgaagttga cttactcgag taagtcaact tcaatgtcgg atttttg          57


<210> 6
<211> 58
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 6
ccggcccaag atagttaagt gggatctcga gatcccactt aactatcttg ggtttttg         58


<210> 7
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 7
ccgggaccat agactggaag gtcttctcga gaagaccttc cagtctatgg tcttttt          57


<210> 8
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 8
ccggccacca agtatggcaa catgactcga gtcatgttgc catacttggt ggttttt          57


<210> 9
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 9
ccggcgcgac cttatctcca acaatctcga gattgttgga gataaggtcg cgttttt          57


<210> 10
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 10
ccggccacac agctacagct ttcttctcga gaagaaagct gtagctgtgt ggttttt          57


<210> 11
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 11
ccgggagaac ctgagacacc ttaagctcga gcttaaggtg tctcaggttc tcttttttg        59


<210> 12
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 12
ctggtctttc tatctcttgt actcgagtac aagagataga aagaccag                    48


<210> 13
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 13
gaccatagac tggaaggtct tctcgagaag accttccagt ctatggtc                    48


